Related Experiment Video
Updated: Jul 17, 2026
08:47
Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
Published on: September 28, 2022
Simulation study of the relationship between variation in bioavailability and clinical equivalence using a direct
Y Matsumoto1, M Shimizu, H Ogata
1Department of Clinical Pharmacology and Toxicology, Showa Pharmaceutical University, Machida, Tokyo, Japan. matsuy@ac.shoyaku.ac.jp
International Journal of Clinical Pharmacology and Therapeutics
|February 12, 2005
Summary
The 80-120% bioequivalence (BE) range may not guarantee clinical equivalence for all drugs. Simulations show that drug properties can affect whether BE ensures therapeutic efficacy, highlighting limitations in current standards.
Area of Science:
- Pharmacokinetics and Pharmacodynamics
- Drug Regulatory Science
- Computational Biology
Background:
- The standard bioequivalence (BE) range of 80-120% is globally applied to ensure therapeutic efficacy.
- However, the direct link between pharmacokinetic parameters and clinical outcomes requires further investigation.
Purpose of the Study:
- To evaluate if the established 80-120% bioequivalence range reliably ensures clinical equivalence across different drug properties.
- To investigate the relationship between variations in Area Under the Curve (AUC) and Maximum Concentration (Cmax) and their impact on the Area Under the Effect Curve (AUEC).
Main Methods:
- Utilized a one-compartment pharmacokinetic model and a sigmoid Emax pharmacodynamic model.
- Employed simulation techniques to assess the influence of AUC and Cmax variations (80-120%) on AUEC.
- Varied total clearance and Cmax under constant AUC conditions to model drug behavior.
Main Results:
- When the shape factor (Y) is less than 1, AUEC remains within acceptable bioequivalence limits if AUC and Cmax are within the 80-120% range.
- When Y is greater than 1 and Cmax is below the EC50, AUEC may fall outside acceptable limits even if AUC and Cmax are within the bioequivalence range.
Conclusions:
- The findings indicate that a 20% variation allowed in bioequivalence testing does not uniformly guarantee clinical equivalence for all pharmaceutical products.
- Drug-specific characteristics, such as the shape factor and its relation to EC50 and Cmax, are critical in determining clinical outcomes beyond standard bioequivalence metrics.
Related Concept Videos
01:27Bioavailability Study Design: Absolute Versus Relative Bioavailability
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:20Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
01:17Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
01:16Bioequivalence Data: Statistical Interpretation
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...